Opens in a new tab
Monday, 16 November 2026
EVIDENCE. INTERPRETED.
Policy & Acquisitions

Mergers & Acquisitions

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Mergers & Acquisitions

214 stories · every one Fact-Checked
AbbVie US Headquarters Angle 3Mergers & AcquisitionsAbbVie to Acquire Apogee Therapeutics for $10.9B, Expanding Immunology and Respiratory PipelineAbbVie has agreed to acquire Apogee Therapeutics in an all-cash deal valued at $10.9 billion, bringing differentiated antibody programs into its immunology and respiratory portfolio.22 Jun 2026 · 4 min read
Fact-Checked
image_4c51480eGenericsSamsung Bioepis and Organon Expand Canadian Biosimilar Portfolio with PYZCHIVASamsung Bioepis and Organon have expanded their Canadian biosimilar partnership to include PYZCHIVA® (ustekinumab), a biosimilar referencing STELARA®.19 Jun 2026 · 3 min read
Fact-Checked
Asian scientists in lab coats discussing research with a microscope in a laboratory setting.Mergers & AcquisitionsVoro and Alloy Partner to Develop Safer T-Cell Engager TherapiesVoro and Alloy have formed a strategic collaboration to advance tumor-activated T-cell engagers. By combining Voro’s PrimeBody masking platform with Alloy’s CD3 antibody engineering, the companies aim to…18 Jun 2026 · 2 min read
Fact-Checked
2149126946Mergers & AcquisitionsBiogen to Acquire RayThera in Up to $1 Billion Deal, Expanding Immunology Pipeline with Phase 1-Ready AssetsBiogen will acquire RayThera in a deal valued up to $1 billion, adding a portfolio of anti-inflammatory small molecules to its immunology pipeline.18 Jun 2026 · 3 min read
Fact-Checked
image_ec0b97ddMergers & AcquisitionsJazz and AbCellera Partner to Develop T-Cell Engagers for GI and Solid Tumors in Deal Worth Up to $792 Million per ProgramJazz Pharmaceuticals and AbCellera have formed a strategic research and licensing collaboration to advance multispecific T-cell engagers for gastrointestinal cancers and other solid tumors.17 Jun 2026 · 3 min read
Fact-Checked
Detailed view of a semaglutide injection pen, commonly used for diabetes treatment, on a plain background.Mergers & AcquisitionsRichter and Hetero Team Up on Generic Semaglutide for Global MarketsGedeon Richter and Hetero announced a global collaboration to develop, register, and commercialize a proposed generic semaglutide injection.12 Jun 2026 · 3 min read
Fact-Checked
image_af7dbfc5Mergers & AcquisitionsServier, n-Lorem Launch ASO Research Partnership in Rare NeurologyServier has partnered with the n‑Lorem Foundation to accelerate antisense oligonucleotide (ASO) therapies for rare genetic neurodevelopmental disorders.11 Jun 2026 · 3 min read
Fact-Checked
Gemini_Generated_Image_gp1mqrgp1mqrgp1mMergers & AcquisitionsNovartis Expands Orionis Partnership in $1.4 Billion Molecular Glue Drug Discovery DealNovartis has deepened its collaboration with Orionis Biosciences in a multi‑year agreement worth up to $1.4 billion, combining Novartis’ development scale with Orionis’ AI‑enabled Allo‑Glue™ platform.11 Jun 2026 · 2 min read
Fact-Checked
image_4756a484Mergers & AcquisitionsLilly Signs Potential $1 Billion Alzheimer’s Deal With AlzeCureEli Lilly and Company has secured global rights to AlzeCure Pharma’s investigational Alzheimer’s therapy ACD680 in a licensing deal worth over $1 billion.10 Jun 2026 · 3 min read
Fact-Checked
Illustration of GSK's Jemperli (dostarlimab) immunotherapy for stage II/III dMMR/MSI-H locally advanced rectal cancer following positive Phase II AZUR-1 trial results.Mergers & AcquisitionsGSK Acquires Nuvalent, Adding FDA-Reviewed ROS1 and ALK InhibitorsGSK has agreed to acquire Nuvalent in a $10.6B cash deal, securing FDA-reviewed NSCLC therapies zidesamtinib and neladalkib.9 Jun 2026 · 3 min read
Fact-Checked
Johnson and Johnson_Photo_WHQ Campus SignageMergers & AcquisitionsJohnson & Johnson Acquires Firefly Bio in $1 Billion Oncology DealJohnson & Johnson has agreed to acquire Firefly Bio for $1 billion, bringing the Firelink™ degrader antibody conjugate platform into its oncology portfolio.9 Jun 2026 · 3 min read
Fact-Checked
Roche's obinutuzumab anti-CD20 therapy receives positive CHMP recommendation for systemic lupus erythematosus.Mergers & AcquisitionsRoche Licenses Nurix’s BTK Degrader Bexobrutideg in Up to $2.3 Billion DealRoche has secured global rights to Nurix’s BTK degrader bexobrutideg (NX‑5948) in a deal worth up to $2.3 billion.8 Jun 2026 · 3 min read
Fact-Checked
Page 10 of 18